BioXcel Therapeutics (BTAI) Change in Accured Expenses (2017 - 2026)

BioXcel Therapeutics has reported Change in Accured Expenses for 10 years, with the latest figure at $1.8 million in Q2 2026.

• On a quarterly basis, Change in Accured Expenses fell 20.79% year-over-year to $1.8 million in Q2 2026; TTM through Jun 2026 was $11.0 million, a 321.92% increase from a year earlier, with the FY2025 full-year figure at $7.0 million, up 261.15% from the prior year.
• Change in Accured Expenses was $1.8 million for Q2 2026 at BioXcel Therapeutics, down from $2.2 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $9.2 million in Q4 2022, with the low at -$12.3 million in Q4 2023.
• Average Change in Accured Expenses over 5 years is $916944.4, with a median of $1.2 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses surged 2458.33% in 2022, then slumped 588.46% in 2023.
• Over 5 years, Change in Accured Expenses stood at $9.2 million in 2022, then slumped by 233.37% to -$12.3 million in 2023, then surged by 72.96% to -$3.3 million in 2024, then surged by 340.6% to $8.0 million in 2025, then sank by 77.12% to $1.8 million in 2026.
• The last three Change in Accured Expenses figures came in at $1.8 million (Q2 2026), $2.2 million (Q1 2026), and $8.0 million (Q4 2025), per Business Quant data.